Appendix Table 1.
aGVHD in TME(+) patients compared to aGVHD in TME(−) patients, restricted to subsets of (a) all patients, (b) patients with no history of pre-transplant GVHD, (c) patients receiving transplants from maternal donors, (d) patients receiving T cell depleted transplants, (e) patients receiving cytotoxic chemotherapy, (f) patients receiving serotherapy, (g) patients for whom TME was determined by STR method, (h) patients receiving transplants from non-maternal donors.
| a | |||||
|---|---|---|---|---|---|
| All Patients | N (%) | TME+ N (%) |
TME− N(%) |
RR (95%CI) | p |
| 74 | 35 | 39 | |||
| aGVHD I–IV | 27 (36.5) | 20 (57.1) | 7 (17.9) | 3.2 (1.5–6.6) | 0.0006 |
| aGVHD II–IV | 21 (28.4) | 15 (42.9) | 6 (15.4) | 2.8 (1.2–6.4) | 0.011 |
| aGVHD III–IV | 7 (9.5) | 5 (14.3) | 2 (5.1) | 2.8 (0.58–13) | 0.24 |
| cGVHD (N=35, 37)^ | 6 (8.1) | 4 (11.4) | 2 (5.4) | 2.1 (0.41–11) | 0.42 |
| b | |||||
|---|---|---|---|---|---|
| No Pre-Transplant GVHD |
N (%) | TME+ N (%) |
TME− N(%) |
RR | p |
| 66 | 27 | 39 | |||
| aGVHD I–IV | 24 (36.4) | 16 (59.3) | 8 (20.5) | 2.9 (1.4–5.8) | 0.0018 |
| aGVHD II–IV | 19 (28.8) | 13 (48.1) | 6 (15.4) | 3.1 (1.4–7.2) | 0.0057 |
| aGVHD III–IV | 6 (9.1) | 4 (14.8) | 2(5.1) | 2.9 (0.57–15) | 0.22 |
| cGVHD (N=27, 37)^ | 5 (7.6) | 3 (11.1) | 2 (5.4) | 2.1 (0.37–11) | 0.64 |
| c | |||||
|---|---|---|---|---|---|
| Maternal Donors | N (%) | TME+ N (%) |
TME− N(%) |
RR | p |
| 44 | 29 | 15 | |||
| aGVHD I–IV | 22 (50.0) | 19(65.5) | 3(20.0) | 3.8 (1.2–9.3) | 0.0097 |
| aGVHD II–IV | 17(38.6) | 14(48.3) | 3 (20.0) | 2.4 (0.82–7.1) | 0.10 |
| aGVHD III–IV | 5 (11.4) | 5 (17.2) | 0 (0) | 7.0 (0.36–135) | 0.15 |
| cGVHD (N=29, 14)^ | 4 (9.1) | 3 (10.3) | 1 (7.1) | 1.4 (0.17–13) | 0.74 |
| d | |||||
|---|---|---|---|---|---|
| TCD | N (%) | TME+ N (%) |
TME− N(%) |
RR | p |
| 50 | 30 | 20 | |||
| aGVHD I–IV | 25 (50.0) | 20 (66.6) | 5 (25.0) | 2.7 (1.2–5.9) | 0.009 |
| aGVHD II–IV | 19 (38.0) | 15 (50) | 4 (20.0) | 2.5 (0.97–6.4) | 0.04 |
| aGVHD III–IV | 6 (12.0) | 5 (16.6) | 1 (5.0) | 3.3 (0.42–28) | 0.38 |
| cGVHD (N=30, 18)^ | 5 (10.0) | 4 (13.3) | 1 (5.6) | 2.7 (0.32–22) | 0.64 |
| e | |||||
|---|---|---|---|---|---|
| Cytotoxic Conditioning | N (%) | TME+ N (%) |
TME− N(%) |
RR | p |
| 23 | 7 | 16 | |||
| aGVHD I–IV | 8 (34.8) | 5 (71.4) | 3 (18.8) | 3.8 (1.2–12) | 0.026 |
| aGVHD II–IV | 5 (21.7) | 3 (42.9) | 2 (12.5) | 3.4 (0.73–16) | 0.14 |
| aGVHD III–IV | 2 (8.7) | 2 (28.6) | 0 (0) | NA | NA |
| cGVHD (N=7, 15)^ | 2 (9.1) | 1 (14.3) | 1 (6.7) | 2.1 (0.16–30) | 1.0 |
| f | |||||
|---|---|---|---|---|---|
| Serotherapy Conditioning |
N (%) | TME+ N (%) |
TME− N(%) |
RR | p |
| 31 | 10 | 21 | |||
| aGVHD I–IV | 7 (22.6) | 3 (30.0) | 4 (19.0) | 1.6 (0.43–5.7) | 0.65 |
| aGVHD II–IV | 4 (12.9) | 2 (20.0) | 2 (9.5) | 2.1 (0.34–13) | 0.58 |
| aGVHD III–IV | 1 (3.2) | 1 (10.0) | 0 (0) | NA | 0.32 |
| cGVHD (N=10, 20)^ | 3 (9.7) | 1 (10.0) | 2 (10.5) | 1.0 (0.08 – 13) | 1.0 |
| g | |||||
|---|---|---|---|---|---|
| STR Analysis | N (%) | TME+ N (%) |
TME− N(%) |
RR | p |
| 38 | 19 | 19 | |||
| aGVHD I–IV | 17 (44.8) | 14 (73.7) | 3 (15.8) | 4.7 (1.6 – 14) | 0.0008 |
| aGVHD II–IV | 11 (28.9) | 9 (47.4) | 2 (10.5) | 4.5 (1.1–18) | 0.03 |
| aGVHD III–IV | 5 (13.2) | 4 (21.1) | 1 (5.3) | 4.0 (0.49–33) | 0.34 |
| cGVHD (N=19, 17)^ | 4 (11.1) | 2 (10.5) | 2 (11.8) | 0.89 (0.14 – 5.7) |
1.0 |
| h | |||||
|---|---|---|---|---|---|
| Non-Maternal Donors | N (%) | TME+ N (%) |
TME− N(%) |
RR | p |
| 30 | 6 | 24 | |||
| aGVHD I–IV | 6 (20) | 1 (16.7) | 5 (20.1) | 0.8 (0.11–5.6) | 0.82 |
| aGVHD II–IV | 4 (13.3) | 1 (16.7) | 3 (12.5) | 1.3 (0.17–10.7) | 0.79 |
| aGVHD III–IV | 2 (6.7) | 0 (0) | 2 (8.3) | 0.7 (0.04 – 13) | 0.82 |
| cGVHD (N=6, 23)^ | 2 (6.9) | 1 (16.7) | 1 (4.3) | 4.6 (0.34–62) | 0.25 |
^
cGVHD outcome was restricted to evaluable patients surviving >100 days post-HSCT.